Pfizer, Inc.
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
企業詳細臨床日程
銘柄カテゴリー
臨床日程
- 2026年8月23日予定
PFE第1相・第2相がん・腫瘍Active Not Recruiting - 2026年8月24日予定
AZN第3相がん・腫瘍Active Not Recruiting AstraZeneca PLC
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
企業詳細 - 2026年8月26日予定
AMGN第1相心臓・循環器Active Not Recruiting Amgen Inc.
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
企業詳細 - 2026年8月28日予定
AZN第1相・第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
企業詳細 - 2026年8月28日予定
AZN第1相医療機器・ヘルスケアActive Not Recruiting AstraZeneca PLC
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
企業詳細 - 2026年8月30日予定
AZN第1相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Selumetinib and Olaparib in Solid Tumors
企業詳細 - 2026年8月30日予定
MRK第2相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
企業詳細 - 2026年8月30日予定
PFE第3相がん・腫瘍Recruiting Pfizer, Inc.
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
企業詳細 - 2026年8月30日予定
PFE段階未分類がん・腫瘍Active Not Recruiting Pfizer, Inc.
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
企業詳細 - 2026年8月31日予定
AZN第1相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
企業詳細 - 2026年8月31日予定
AZN第3相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
企業詳細 - 2026年8月31日予定
AZN段階未分類がん・腫瘍Active Not Recruiting AstraZeneca PLC
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
企業詳細 - 2026年8月31日予定
AZN段階未分類がん・腫瘍Active Not Recruiting AstraZeneca PLC
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
企業詳細 - 2026年8月31日予定
NVO段階未分類糖尿病・代謝Enrolling By Invitation Novo Nordisk A/S
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
企業詳細 - 2026年8月31日予定
PFE第3相免疫・炎症Recruiting Pfizer, Inc.
A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
企業詳細 - 2026年8月31日予定
PFE第1相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
企業詳細 - 2026年9月予定
ABBV第1相がん・腫瘍Active Not Recruiting AbbVie Inc.
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
企業詳細 - 2026年9月予定
ABBV第2相がん・腫瘍Active Not Recruiting AbbVie Inc.
Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer
企業詳細 - 2026年9月予定
ABBV第3相免疫・炎症Recruiting AbbVie Inc.
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
企業詳細 - 2026年9月予定
ABBV第1相医療機器・ヘルスケアActive Not Recruiting AbbVie Inc.
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
企業詳細 - 2026年9月予定
ABBV段階未分類免疫・炎症Recruiting AbbVie Inc.
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
企業詳細 - 2026年9月予定
ABBV第1相医療機器・ヘルスケアRecruiting AbbVie Inc.
A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants
企業詳細 - 2026年9月予定
ABBV第1相医療機器・ヘルスケアRecruiting AbbVie Inc.
A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants
企業詳細 - 2026年9月予定
ALKS第3相脳・神経・睡眠Recruiting Alkermes plc
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
企業詳細 - 2026年9月予定
AZN第1相・第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
企業詳細 - 2026年9月予定
AZN第1相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma
企業詳細 - 2026年9月予定
AZN第1相・第2相がん・腫瘍Recruiting AstraZeneca PLC
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
企業詳細 - 2026年9月予定
AZN第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
企業詳細 - 2026年9月予定
AZN第2相がん・腫瘍Enrolling By Invitation AstraZeneca PLC
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
企業詳細 - 2026年9月予定
AZNNA心臓・循環器Recruiting AstraZeneca PLC
Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)
企業詳細 - 2026年9月予定
AZN第4相医療機器・ヘルスケアRecruiting AstraZeneca PLC
Characterizing the Human Airway Immune Response to FluMist Vaccination
企業詳細 - 2026年9月予定
GILD第3相免疫・炎症Active Not Recruiting Gilead Sciences, Inc.
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
企業詳細 - 2026年9月予定
GILD第2相感染症・ワクチンActive Not Recruiting Gilead Sciences, Inc.
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
企業詳細 - 2026年9月予定
LLY段階未分類がん・腫瘍Recruiting Eli Lilly and Company
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
企業詳細 - 2026年9月予定
LLY第2相糖尿病・代謝Active Not Recruiting Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
企業詳細 - 2026年9月予定
LLY第1相医療機器・ヘルスケアRecruiting Eli Lilly and Company
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
企業詳細 - 2026年9月予定
LLY第3相免疫・炎症Active Not Recruiting Eli Lilly and Company
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
企業詳細 - 2026年9月予定
LLY段階未分類医療機器・ヘルスケアNot Yet Recruiting Eli Lilly and Company
A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease
企業詳細 - 2026年9月予定
LLY第1相医療機器・ヘルスケアActive Not Recruiting Eli Lilly and Company
A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants
企業詳細 - 2026年9月予定
LNTH第4相がん・腫瘍Active Not Recruiting Lantheus Holdings, Inc.
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
企業詳細 - 2026年9月予定
LNTH第1相心臓・循環器Recruiting Lantheus Holdings, Inc.
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
企業詳細 - 2026年9月予定
MAZE第2相心臓・循環器Recruiting Maze Therapeutics, Inc.
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
企業詳細 - 2026年9月予定
MRK第1相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
企業詳細 - 2026年9月予定
MRK第2相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
企業詳細 - 2026年9月予定
MRKNA脳・神経・睡眠Recruiting Merck & Company, Inc.
Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis
企業詳細 - 2026年9月予定
MRK段階未分類医療機器・ヘルスケアRecruiting Merck & Company, Inc.
Characterization, Health Resource Utilization and Biomarkers in Early-stage
企業詳細 - 2026年9月予定
NVONA医療機器・ヘルスケアRecruiting Novo Nordisk A/S
The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy
企業詳細 - 2026年9月予定
NVS段階未分類免疫・炎症Recruiting Novartis AG
ITP Registry and Accompanying Biospecimen Collection
企業詳細 - 2026年9月予定
PFENA心臓・循環器Active Not Recruiting Pfizer, Inc.
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
企業詳細 - 2026年9月予定
PFE第4相脳・神経・睡眠Recruiting Pfizer, Inc.
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
企業詳細 - 2026年9月予定
SNDX第2相がん・腫瘍Active Not Recruiting Syndax Pharmaceuticals, Inc.
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
企業詳細 - 2026年9月1日予定
GILD第4相免疫・炎症Recruiting Gilead Sciences, Inc.
HIV Prevention With PrEP Among People on Opioid Replacement Therapy
企業詳細 - 2026年9月1日予定
LNTH段階未分類糖尿病・代謝Enrolling By Invitation Lantheus Holdings, Inc.
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
企業詳細 - 2026年9月1日予定
MRK第3相感染症・ワクチンActive Not Recruiting Merck & Company, Inc.
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
企業詳細 - 2026年9月1日予定
NVO第2相糖尿病・代謝Recruiting Novo Nordisk A/S
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
企業詳細 - 2026年9月1日予定
PFE第1相・第2相がん・腫瘍Active Not Recruiting Pfizer, Inc.
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
企業詳細 - 2026年9月2日予定
MRK第2相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
企業詳細 - 2026年9月2日予定
MRK第1相医療機器・ヘルスケアActive Not Recruiting Merck & Company, Inc.
A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
企業詳細 - 2026年9月3日予定
AMGN第1相医療機器・ヘルスケアActive Not Recruiting Amgen Inc.
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
企業詳細 - 2026年9月3日予定
AZN第1相脳・神経・睡眠Active Not Recruiting AstraZeneca PLC
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
企業詳細 - 2026年9月3日予定
MRK第1相糖尿病・代謝Active Not Recruiting Merck & Company, Inc.
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
企業詳細 - 2026年9月3日予定
MRK第1相医療機器・ヘルスケアActive Not Recruiting Merck & Company, Inc.
A Study of MK-7240 in Healthy Participants (MK-7240-009)
企業詳細 - 2026年9月3日予定
NVO第1相糖尿病・代謝Active Not Recruiting Novo Nordisk A/S
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
企業詳細 - 2026年9月3日予定
PFE第1相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults
企業詳細 - 2026年9月5日予定
MRK第2相免疫・炎症Active Not Recruiting Merck & Company, Inc.
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
企業詳細 - 2026年9月5日予定
MRK第1相医療機器・ヘルスケアActive Not Recruiting Merck & Company, Inc.
A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
企業詳細 - 2026年9月7日予定
AZN第1相医療機器・ヘルスケアActive Not Recruiting AstraZeneca PLC
A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults
企業詳細 - 2026年9月10日予定
PFE第1相医療機器・ヘルスケアNot Yet Recruiting Pfizer, Inc.
A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults
企業詳細 - 2026年9月12日予定
NVO第1相糖尿病・代謝Active Not Recruiting Novo Nordisk A/S
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
企業詳細 - 2026年9月12日予定
PFE第1相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women
企業詳細 - 2026年9月14日予定
MRK第1相感染症・ワクチンActive Not Recruiting Merck & Company, Inc.
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
企業詳細 - 2026年9月15日予定
MRK第3相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
企業詳細 - 2026年9月15日予定
PFE第1相・第2相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
企業詳細 - 2026年9月17日予定
AZN第1相医療機器・ヘルスケアActive Not Recruiting AstraZeneca PLC
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
企業詳細 - 2026年9月21日予定
MRK第1相感染症・ワクチンRecruiting Merck & Company, Inc.
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
企業詳細 - 2026年9月21日予定
PFE段階未分類感染症・ワクチンRecruiting Pfizer, Inc.
A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.
企業詳細
